{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:55:24Z","timestamp":1790420124840,"version":"4.1.0"},"reference-count":59,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,8,31]],"date-time":"2011-08-31T00:00:00Z","timestamp":1314748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> Ceftriaxone, a third\u2010generation cephalosporin, is commonly used to prevent and treat infections. Since 1987, it has been the second most common cause of drug\u2010induced immune hemolytic anemia (DIIHA) investigated in our laboratory.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> Samples from 79 patients (1987\u20102010), suspected of having DIIHA caused by ceftriaxone, were studied for the presence of ceftriaxone antibodies. Direct antiglobulin tests (DATs) and tests with ceftriaxone\u2010treated red blood cells (RBCs) or untreated and enzyme\u2010treated RBCs in the presence of ceftriaxone were performed.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> Twenty\u2010five (32%) of the 79 patients had antibodies to ceftriaxone detected. Seventeen (68%) of the 25 patients were children; reactions in children were usually dramatic and severe. Nine (36%) of the 25 patients had fatal DIIHA. Nineteen of the 25 samples had DATs performed by our laboratory; 100% of samples were reactive with anti\u2010C3 and 47% were reactive with anti\u2010IgG. All 25 sera had ceftriaxone antibodies detected when testing untreated or ficin\u2010treated RBCs in the presence of ceftriaxone (resulting in agglutination, hemolysis or sensitization of test RBCs). These antibodies were primarily IgM and reactivity was enhanced by testing ficin\u2010treated RBCs. Sixteen (64%) of the 25 sera reacted with test RBCs when no ceftriaxone was added in vitro; this was most likely due to the transient presence of drug or drug\u2010immune complexes in the patient's circulation at the time that the blood samples were drawn.<\/jats:p><jats:p><jats:bold>CONCLUSION:<\/jats:bold> Ceftriaxone antibodies can cause severe intravascular hemolysis. Complement can usually be detected on the patient's RBCs and IgM antibodies are usually detected in the patient's serum.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2011.03321.x","type":"journal-article","created":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T06:41:19Z","timestamp":1314859279000},"page":"602-612","source":"Crossref","is-referenced-by-count":36,"title":["Serologic characteristics of ceftriaxone antibodies in 25 patients with drug\u2010induced immune hemolytic anemia (CME)"],"prefix":"10.1111","volume":"52","author":[{"given":"Patricia A.","family":"Arndt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina M.","family":"Leger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Garratty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,8,31]]},"reference":[{"key":"e_1_2_8_2_2","first-page":"2859","volume-title":"Physicians' desk reference","year":"2010"},{"key":"e_1_2_8_3_2","first-page":"98","article-title":"Drug\u2010induced immune hemolytic anemia","volume":"8","author":"Garratty G","year":"2010","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1991.31291142951.x"},{"key":"e_1_2_8_5_2","first-page":"25S","article-title":"Ceftriaxone induced hemolytic anemia. (abstract)","volume":"33","author":"Lo G","year":"1993","journal-title":"Transfusion"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199512000-00023"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(95)70417-5"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(98)70236-7"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01434.x"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200001000-00019"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001340000598"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2000.40121543.x"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2002.43.3.391"},{"key":"e_1_2_8_14_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.21307\/immunohematology-2019-504","article-title":"Practical aspects of investigating drug\u2010induced immune hemolytic anemia due to cefotetan or ceftriaxone\u2014a case study approach","volume":"18","author":"Arndt PA","year":"2002","journal-title":"Immunohematology"},{"key":"e_1_2_8_15_2","first-page":"96S","article-title":"Self\u2010limited immune hemolysis in a child after six days of ceftriaxone therapy. (abstract)","volume":"42","author":"Eastlund T","year":"2002","journal-title":"Transfusion"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1754.2002.00778.x"},{"key":"e_1_2_8_17_2","doi-asserted-by":"crossref","first-page":"905","DOI":"10.5858\/2004-128-905-ACOAHA","article-title":"A case of acute hemolysis after ceftriaxone. Immune complex mechanism demonstrated by flow cytometry","volume":"128","author":"Kakaiya R","year":"2004","journal-title":"Arch Pathol Lab Med"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/000992280404300207"},{"key":"e_1_2_8_19_2","first-page":"32A","article-title":"Drug\u2010induced immune hemolytic anemia presenting as cold agglutinin syndrome. (abstract)","volume":"44","author":"Johnson ST","year":"2004","journal-title":"Transfusion"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.PCC.0000161285.12396.FF"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.pec.0000159053.64930.2d"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-006-0043-4"},{"issue":"3","key":"e_1_2_8_23_2","first-page":"144","article-title":"Adverse haemolytic transfusion events: consider the role of drugs [abstract]","volume":"91","author":"van den Bos AG","year":"2006","journal-title":"Vox Sang"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181629a55"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2008.01656.x"},{"key":"e_1_2_8_26_2","first-page":"610","article-title":"Hemolytic anemia from ceftriaxone in an elderly patient: a case report","author":"Imam SN","year":"2008","journal-title":"JAMDA"},{"key":"e_1_2_8_27_2","first-page":"13A","article-title":"Successful treatment of life\u2010threatening ceftriaxone\u2010induced hemolysis by plasmapheresis in a 4\u2010year old girl [abstract]","volume":"49","author":"Doratotaj S","year":"2009","journal-title":"Transfusion"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181b7eda2"},{"key":"e_1_2_8_29_2","first-page":"21","article-title":"A fatal case of ceftriaxone\u2010induced autoimmune hemolytic anemia","author":"Williams CS","year":"2009","journal-title":"Hospital Physician"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02639.x"},{"key":"e_1_2_8_31_2","volume-title":"Immune hemolytic anemias","author":"Petz LD","year":"2004"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.73"},{"key":"e_1_2_8_33_2","first-page":"1967","volume-title":"The Merck index","author":"O'Neil MJ","year":"2001"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1981.21281178150.x"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1998.38698326336.x"},{"key":"e_1_2_8_36_2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.4049\/jimmunol.97.6.791","article-title":"The use of a water\u2010soluble carbodiimide as a coupling reagent in the passive hemagglutination test","volume":"97","author":"Johnson HM","year":"1966","journal-title":"J Immunol"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1992.32692367200.x"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1976.tb02806.x"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1976.tb02821.x"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1999.39111239.x"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1309\/JFJE-VUKN-221T-G6EV"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00562.x"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/76.1.73"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1984.24384225022.x"},{"key":"e_1_2_8_45_2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/ajcp\/84.3.391","article-title":"Immune hemolytic anemia associated with probenicid","volume":"84","author":"Sosler SD","year":"1985","journal-title":"Am J Clin Pathol"},{"key":"e_1_2_8_46_2","first-page":"860","article-title":"Immunologic cross\u2010reactivity of cephalexin and penicillin","volume":"83","author":"Petersen BH","year":"1974","journal-title":"J Lab Clin Med"},{"key":"e_1_2_8_47_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.21307\/immunohematology-2019-328","article-title":"An update of drug\u2010induced immune hemolytic anemia","volume":"23","author":"Garratty G","year":"2007","journal-title":"Immunohematology"},{"key":"e_1_2_8_48_2","first-page":"320","article-title":"Etude in vitro de la fixation sanguine de la ceftriaxone","volume":"34","author":"Brandebourger M","year":"1986","journal-title":"Pathol Biol (Paris)"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600781005"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.20.5.634"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2010.01061.x"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01173.x"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/89.3.410"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01644237"},{"key":"e_1_2_8_55_2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.21307\/immunohematology-2019-335","article-title":"Warm autoantibody or drug\u2010dependent antibody? That is the question!","volume":"23","author":"Johnson ST","year":"2007","journal-title":"Immunohematology"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/161454"},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(66)92423-8"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.1998.7420122.x"},{"key":"e_1_2_8_59_2","first-page":"426","article-title":"Massive immune hemolysis, disseminated intravascular coagulation (DIC), and acute renal failure in association with tolmetin ingestion [abstract]","volume":"24","author":"Leitman SF","year":"1984","journal-title":"Transfusion"},{"key":"e_1_2_8_60_2","first-page":"33A","article-title":"Serologic characteristics of anti\u2010ceftriaxone in a large series of patients with drug\u2010induced immune hemolytic anemia [abstract]","volume":"49","author":"Arndt PA","year":"2009","journal-title":"Transfusion"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2011.03321.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2011.03321.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T20:08:31Z","timestamp":1697314111000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2011.03321.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,31]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1111\/j.1537-2995.2011.03321.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2011.03321.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,31]]}}}